Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101467 | 0.92 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3GRM5SSTR3 | |
| SCHEMBL6098272 | 0.90 | GRM5 (0.38) | HTR3AGRM5EZH2 | |
| SCHEMBL7123918 | 0.88 | CHRNB4 (0.34) | HTR3AGRM5SSTR3CHRNB4CHRNA3 | |
| SCHEMBL7123424 | 0.88 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3HTR3AGRM5 | |
| SCHEMBL6099256 | 0.86 | SSTR3 (0.40) | SLC6A4SLC6A3GRM5SSTR3 | |
| SCHEMBL7120687 | 0.85 | KDM2B (0.39) | HTR3AGRM5SSTR3CHRNB4CHRNA3 | |
| SCHEMBL7124744 | 0.84 | DRD4 (0.39) | SLC6A2SLC6A4SLC6A3HTR3AGRM5 | |
| SCHEMBL7115114 | 0.84 | GRM5 (0.37) | SLC6A2SLC6A4SLC6A3HTR3AGRM5 | |
| SCHEMBL7120585 | 0.84 | SLC6A3 (0.38) | SLC6A2SLC6A4SLC6A3HTR3AGRM5 | |
| SCHEMBL6101324 | 0.84 | CYP2C9 (0.37) | HTR3AGRM5SSTR3CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | SLC6A2 1156/4885SLC6A4 2137/4885SLC6A3 2265/4885 |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | SLC6A2 1361/4885SLC6A4 2113/4885SLC6A3 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.